Febrile Neutropenia Risk Tool

BeCOn Febrile Neutropenia Risk Assessment. The application allows you to assess if a patient undergoing chemotherapy is at risk of febrile neutropenia. Through a series of standardised questions based on EORTC and NCCN guidelines, the tool asks you consider the numerous factors that may contribute to an increased risk.
Benefits

·It allows you to reference the EORTC and NCCN estimated risk associated with Febrile Neutropenia across all of the major chemotherapy regimes.

·All of the content is accessible via your mobile device, this means you can access the content “on the go”, to allow for fast, efficient decision making.

BeCOn
This tool is offered to you as part of Teva’s BeCOn initiative. BeCOn (Building Excellence and Continuity in Oncology Care) is our commitment to support the patient and the Health Care Professional across the continuum of care throughout the patient journey.